Stock listing
NASDAQ:ORMP Oramed Pharmaceuticals Inc. Stock
Home listing (NASDAQ) of Oramed Pharmaceuticals Inc.
Follow Oramed Pharmaceuticals Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ORMP
$3.57 USD -0.32 (-8.2%)
Close on Nov 20, 2026
- Day range
- $3.54 – $3.71 USDNov 20, 2026
- Volume
- 285,666 sharesNov 20, 2026
- Market cap
- $155.2M USDAt the close on Nov 20, 2026 · price × 43.49M shares outstanding
- 52-week range
- $2.40 – $5.47 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $774,468 USDMedian day 135,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ORMP · Home | $3.57 USD | -0.32 (-8.2%) | 285,666 | $3.67 | $3.71 | $3.544 | $3.89 | Close on Nov 20, 2026 |
| TASE:ORMP | 1,248.00 ILA (agorot) | -6.00 (-0.5%) | 2,006 | 1,254.00 | 1,266.00 | 1,241.00 | 1,254.00 | Close on Nov 19, 2026 |
| Frankfurt:OJU1 | €3.31 EUR | -0.185 (-5.3%) | — | €3.31 | €3.31 | €3.31 | €3.495 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ORMP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.57 | -0.32 | -8.2% | $3.67 | $3.71 | $3.544 | 285,666 | |
| $3.89 | +0.02 | +0.5% | $3.87 | $3.93 | $3.83 | 164,339 | |
| $3.87 | -0.03 | -0.8% | $3.85 | $3.96 | $3.85 | 186,347 | |
| $3.90 | +0.19 | +5.1% | $3.70 | $4.052 | $3.70 | 346,559 | |
| $3.71 | -0.32 | -7.9% | $4.03 | $4.12 | $3.67 | 160,813 | |
| $4.03 | -0.10 | -2.4% | $4.17 | $4.218 | $3.94 | 111,223 | |
| $4.13 | +0.16 | +4.0% | $3.99 | $4.14 | $3.99 | 105,444 | |
| $3.97 | -0.03 | -0.7% | $3.96 | $3.99 | $3.86 | 80,664 | |
| $4.00 | +0.14 | +3.6% | $3.94 | $4.025 | $3.85 | 112,995 | |
| $3.86 | -0.03 | -0.8% | $3.90 | $4.00 | $3.84 | 112,539 | |
| $3.89 | -0.24 | -5.8% | $4.08 | $4.08 | $3.89 | 189,333 | |
| $4.13 | +0.13 | +3.2% | $4.05 | $4.14 | $4.05 | 119,675 | |
| $4.00 | 0.00 | 0.0% | $4.02 | $4.05 | $3.915 | 116,549 | |
| $4.00 | -0.11 | -2.7% | $4.11 | $4.11 | $4.00 | 97,259 | |
| $4.11 | -0.12 | -2.8% | $4.22 | $4.29 | $4.08 | 91,505 | |
| $4.23 | +0.07 | +1.7% | $4.16 | $4.29 | $4.16 | 91,006 | |
| $4.16 | 0.00 | 0.0% | $4.10 | $4.17 | $4.10 | 55,699 | |
| $4.16 | +0.08 | +2.0% | $4.10 | $4.17 | $4.06 | 97,228 | |
| $4.08 | -0.05 | -1.2% | $4.14 | $4.20 | $4.04 | 109,117 | |
| $4.13 | +0.01 | +0.2% | $4.10 | $4.17 | $4.06 | 115,700 | |
| $4.12 | -0.02 | -0.5% | $4.09 | $4.21 | $4.08 | 97,600 | |
| $4.14 | -0.01 | -0.2% | $4.16 | $4.21 | $4.06 | 84,400 | |
| $4.15 | +0.09 | +2.2% | $4.06 | $4.22 | $4.05 | 142,300 | |
| $4.06 | -0.01 | -0.2% | $4.08 | $4.10 | $3.89 | 162,700 | |
| $4.07 | -0.11 | -2.6% | $4.19 | $4.19 | $3.99 | 277,100 | |
| $4.18 | +0.04 | +1.0% | $4.18 | $4.28 | $4.15 | 128,200 | |
| $4.14 | -0.03 | -0.7% | $4.12 | $4.22 | $4.12 | 146,600 | |
| $4.17 | -0.10 | -2.3% | $4.28 | $4.28 | $4.15 | 113,800 | |
| $4.27 | -0.06 | -1.4% | $4.34 | $4.35 | $4.21 | 73,200 | |
| $4.33 | +0.13 | +3.1% | $4.17 | $4.34 | $4.15 | 193,500 | |
| $4.20 | -0.17 | -3.9% | $4.36 | $4.36 | $4.16 | 166,500 | |
| $4.37 | -0.01 | -0.2% | $4.43 | $4.45 | $4.35 | 84,700 | |
| $4.38 | -0.17 | -3.7% | $4.55 | $4.58 | $4.36 | 96,200 | |
| $4.55 | +0.06 | +1.3% | $4.50 | $4.57 | $4.43 | 104,100 | |
| $4.49 | +0.01 | +0.2% | $4.53 | $4.57 | $4.39 | 178,300 | |
| $4.48 | -0.19 | -4.1% | $4.65 | $4.69 | $4.43 | 272,600 | |
| $4.67 | -0.02 | -0.4% | $4.70 | $4.72 | $4.66 | 129,200 | |
| $4.69 | -0.06 | -1.3% | $4.76 | $4.80 | $4.67 | 170,700 | |
| $4.75 | +0.02 | +0.4% | $4.70 | $4.78 | $4.65 | 110,400 | |
| $4.73 | -0.06 | -1.3% | $4.80 | $4.90 | $4.72 | 177,900 | |
| $4.79 | +0.07 | +1.5% | $4.71 | $4.88 | $4.65 | 149,300 | |
| $4.72 | -0.03 | -0.6% | $4.74 | $4.74 | $4.62 | 134,800 | |
| $4.75 | +0.05 | +1.1% | $4.71 | $4.84 | $4.71 | 145,200 | |
| $4.70 | -0.04 | -0.8% | $4.76 | $4.76 | $4.67 | 97,400 | |
| $4.74 | +0.07 | +1.5% | $4.65 | $4.80 | $4.61 | 804,600 | |
| $4.67 | +0.05 | +1.1% | $4.70 | $4.77 | $4.65 | 128,000 | |
| $4.62 | 0.00 | 0.0% | $4.63 | $4.67 | $4.54 | 122,800 | |
| $4.62 | -0.05 | -1.1% | $4.64 | $4.66 | $4.55 | 142,800 | |
| $4.67 | +0.01 | +0.2% | $4.64 | $4.76 | $4.64 | 135,000 | |
| $4.66 | -0.10 | -2.1% | $4.81 | $4.82 | $4.65 | 144,500 | |
| $4.76 | -0.02 | -0.4% | $4.74 | $4.85 | $4.66 | 131,500 | |
| $4.78 | -0.20 | -4.0% | $4.94 | $4.94 | $4.70 | 244,800 | |
| $4.98 | -0.03 | -0.6% | $4.99 | $5.01 | $4.92 | 118,200 | |
| $5.01 | +0.08 | +1.6% | $4.92 | $5.05 | $4.86 | 226,900 | |
| $4.93 | -0.14 | -2.8% | $5.11 | $5.11 | $4.81 | 188,000 | |
| $5.07 | +0.22 | +4.5% | $4.85 | $5.15 | $4.85 | 188,600 | |
| $4.85 | -0.17 | -3.4% | $5.00 | $5.15 | $4.80 | 255,300 | |
| $5.02 | -0.01 | -0.2% | $5.03 | $5.06 | $4.90 | 242,900 | |
| $5.03 | -0.07 | -1.4% | $5.14 | $5.15 | $5.01 | 154,100 | |
| $5.10 | -0.24 | -4.5% | $5.35 | $5.47 | $5.06 | 276,300 | |
| $5.34 | +0.13 | +2.5% | $5.31 | $5.43 | $5.12 | 400,500 | |
| $5.21 | +0.39 | +8.1% | $4.80 | $5.25 | $4.80 | 641,500 | |
| $4.82 | +0.01 | +0.2% | $4.80 | $4.86 | $4.74 | 90,700 | |
| $4.81 | +0.02 | +0.4% | $4.81 | $4.88 | $4.75 | 126,100 | |
| $4.79 | 0.00 | 0.0% | $4.78 | $4.86 | $4.68 | 177,200 |
Splits
1 split · NASDAQ:ORMP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:ORMP
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Jun 25, 2026
Closed $5.00 (+16.3%) on Jun 25, 2026
Oramed and Lifeward Announce Strategic Transaction
Jan 13, 2026
Closed $3.39 (-1.2%) on Jan 13, 2026
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Jan 13, 2026
Closed $3.39 (-1.2%) on Jan 13, 2026
Oramed Pharmaceuticals Inc. on 6ix
- News releases
- 4 in the last 12 months · 129 in all · newest Jun 25, 2026 · oldest 2019
- Decks
- 36 decks · latest August 2023
Where Oramed Pharmaceuticals Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ORMP · Home listing · This page | NASDAQ | United States | USD |
| TASE:ORMP | TASE | Israel | ILA |
| Tradegate:OJU1 | Tradegate | Germany | EUR |
| Lang & Schwarz:A1CTNU | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1CTNU | LS Exchange | Germany | EUR |
| Frankfurt:OJU1 | Frankfurt | Germany | EUR |
| BOATS:ORMP | BOATS | United States | USD |
| gettex:OJU1 | gettex | Germany | EUR |
| Dusseldorf:OJU1 | Dusseldorf | Germany | EUR |
| Munich:OJU1 | Munich | Germany | EUR |
| Stuttgart:OJU1 | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $127.3M USD
- P/E
- 1.1×
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.21
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 4.47 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Arie Mayer | Managing Director and Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −7.9% |
| Q2 2026 | Aug 10, 2026 · After close | +1.2% |
| Q1 2026 | Jun 3, 2026 | +5.8% |
| Q4 2025 | Mar 26, 2026 · After close | −0.3% |
| Q3 2025 | Nov 13, 2025 · After close | −2.9% |
| Q2 2025 | Aug 14, 2025 · After close | −1.9% |
| Q1 2025 | May 15, 2025 · After close | −2.3% |
| Q4 2024 | Mar 4, 2025 · After close | +7.5% |
| Q3 2024 | Nov 7, 2024 · After close | −2.9% |
| Q2 2024 | Aug 14, 2024 · After close | +4.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +0.8% |
| Q4 2023 | Mar 6, 2024 · After close | −0.3% |
| Q3 2023 | Nov 9, 2023 · After close | −1.5% |
| Q2 2023 | Aug 10, 2023 · After close | +2.5% |
| Q1 2023 | May 11, 2023 · After close | +0.3% |
| Q4 2022 | Mar 6, 2023 · After close | 0.0% |
| Q3 2022 | Nov 10, 2022 · After close | +14.7% |
| Q2 2022 | Aug 10, 2022 · After close | +8.8% |
| Q1 2022 | May 12, 2022 · After close | +10.4% |
| Q4 2021 | Jan 11, 2022 · After close | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2023) | Investor deck | 41 slides | August 2023 |
| Investor Presentation (May 2023) | Investor deck | 41 slides | May 2023 |
| Investor Presentation (December 2022) | Investor deck | 42 slides | December 2022 |
| Investor Presentation (December 2022) | Investor deck | 41 slides | December 2022 |
| Oramed NASH Webinar: Phase 2 Trial Results of ORMD-0801 (November 2022) | Conference | 29 slides | Nov 17, 2022 |
| Investor Presentation (August 2022) | Investor deck | 40 slides | August 2022 |
| Investor Presentation (June 2022) | Investor deck | 40 slides | June 2022 |
| Technical Presentation (June 2022) | Technical | 22 slides | June 2022 |
| Investor Presentation (March 2022) | Investor deck | 40 slides | March 2022 |
| Investor Presentation (December 2021) | Investor deck | 38 slides | Dec 7, 2021 |
All 36 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2021) | Investor deck | 37 slides | September 2021 |
| Investor Presentation (August 2021) | Investor deck | 36 slides | August 2021 |
| Investor Presentation (March 2021) | Investor deck | 43 slides | Mar 19, 2021 |
| Investor Presentation (October 2020) | Investor deck | 42 slides | Oct 22, 2020 |
| EASD 2020 | Conference | 14 slides | September 2020 |
| EASD 2020 | Conference | 14 slides | 2020 |
| Investor Presentation (November 2019) | Investor deck | 37 slides | Nov 18, 2019 |
| Investor Presentation (April 2019) | Investor deck | 44 slides | April 2019 |
| Investor Presentation (February 2019) | Investor deck | 44 slides | February 2019 |
| Investor Presentation (December 2018) | Investor deck | 44 slides | December 2018 |
| Investor Presentation (August 2018) | Investor deck | 44 slides | August 2018 |
| Investor Presentation (June 2017) | Investor deck | 38 slides | June 2017 |
| Technical Presentation (July 2016) | Technical | 10 slides | Jul 28, 2016 |
| Technical Presentation (July 2016) | Technical | 10 slides | Jul 28, 2016 |
| Investor Presentation (May 2016) | Investor deck | 35 slides | May 23, 2016 |
| Investor Presentation (May 2016) | Investor deck | 34 slides | May 2016 |
| Investor Presentation (January 2016) | Investor deck | 34 slides | Jan 14, 2016 |
| Investor Presentation (July 2015) | Investor deck | 38 slides | July 2015 |
| Investor Presentation (December 2014) | Investor deck | 40 slides | Dec 2, 2014 |
| Technical Presentation (November 2014) | Technical | 11 slides | Nov 3, 2014 |
| Investor Presentation (September 2014) | Investor deck | 35 slides | Sep 8, 2014 |
| GTC Diabetes Summit (April 2014) | Conference | 21 slides | Apr 24, 2014 |
| Investor Presentation (February 2014) | Investor deck | 41 slides | Feb 12, 2014 |
| IPO Roadshow (June 2013) | IPO roadshow | 42 slides | Jun 17, 2013 |
| Investor Presentation (September 2010) | Investor deck | 14 slides | Sep 8, 2010 |
| Investor Presentation (July 2008) | Investor deck | 19 slides | Jul 23, 2008 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.00M | 0 | 1.34M | 2.70M | 2.70M | 2.70M | 2.71M | 2.71M | 2.70M | 2.70M |
| Cost of revenue | 1.99M | 193.0K | 90.0K | 90.0K | 90.0K | |||||
| Gross profit | 13.0K | -193.0K | 1.34M | 2.70M | 2.70M | 2.71M | 2.61M | 2.61M | ||
| Research and development | 6.38M | 6.32M | 8.97M | 27.6M | 21.0M | 21.0M | 10.2M | 10.2M | 13.5M | 13.5M |
| Selling, general and administrative | 8.72M | 6.46M | 8.43M | 13.8M | 5.94M | 4.23M | 3.72M | |||
| Operating income | -15.1M | -12.8M | -15.8M | -40.6M | -24.2M | -24.2M | -11.8M | -11.8M | -14.6M | -14.6M |
| Depreciation and amortization | 121.0K | 193.0K | 196.0K | 58.0K | 77.0K | 77.0K | 7.00K | 7.00K | 8.00K | 8.00K |
| EBITDA | -15.0M | -12.6M | -15.6M | -40.5M | -24.1M | -24.1M | -11.8M | -11.8M | -14.6M | -14.6M |
| Interest expense | 0 | 853.0K | 2.04M | 2.93M | 6.00K | 126.0K | ||||
| Income before tax | 75.3M | -15.9M | 5.09M | -37.7M | -23.0M | 5.31M | -11.5M | -11.5M | -14.1M | -14.1M |
| Income tax | 11.3M | 3.18M | 100.0K | -2.88M | 192.0K | 300.0K | 300.0K | |||
| Net income | 64.0M | -19.1M | 5.09M | -36.6M | -22.2M | -23.0M | -11.5M | -11.5M | -14.4M | -14.4M |
| Earnings per share, basic | 1.53 | -0.48 | 0.14 | -0.94 | -0.78 | 0.78 | -0.56 | 0.56 | -0.82 | 0.82 |
| Earnings per share, diluted | 1.50 | -0.48 | 0.14 | -0.94 | 0.78 | 0.56 | 0.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.9M | 54.4M | 9.05M | 40.5M | 77.2M | 77.2M | 19.3M | 19.3M | 3.33M | 3.33M |
| Short-term investments | 5.42M | 3.44M | 57.7M | 3.74M | 16.9M | 5.85M | 20.6M | 3.30M | 29.0M | 3.70M |
| Receivables | 4.64M | |||||||||
| Current assets | 133.3M | 143.2M | 162.6M | 157.1M | 95.3M | 95.3M | 40.5M | 40.5M | 33.3M | 33.3M |
| Property, plant and equipment | 586.0K | 698.0K | 873.0K | 815.0K | 397.0K | 99.0K | 24.0K | |||
| Total assets | 230.9M | 155.3M | 220.6M | 161.6M | 128.0M | 128.0M | 44.6M | 44.6M | 34.7M | 34.7M |
| Accounts payable | 443.0K | 789.0K | 551.0K | 2.17M | 2.61M | 594.0K | 1.34M | |||
| Current liabilities | 19.1M | 5.68M | 53.2M | 5.75M | 6.68M | 6.68M | 4.54M | 4.54M | 5.31M | 5.31M |
| Total debt | 825.0K | 372.0K | 51.6M | 25.0K | 533.0K | 12.5M | 75.0K | 12.4M | ||
| Total liabilities | 31.1M | 9.93M | 57.7M | 10.5M | 11.5M | 11.8M | 15.3M | |||
| Shareholders' equity | 199.7M | 146.3M | 163.8M | 151.8M | 115.8M | 115.8M | 32.9M | 32.9M | 19.4M | 19.4M |
| Shares outstanding | 39.3M | 39.9M | 40.3M | 39.6M | 28.5M | 35.3M | 20.5M | 23.7M | 17.5M | 17.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.14M | -8.41M | -10.3M | -27.9M | -21.2M | -21.2M | -12.4M | -12.4M | -12.9M | -12.9M |
| Capital spending | -9.00K | -18.0K | -254.0K | -496.0K | -375.0K | -375.0K | -82.0K | -82.0K | -15.0K | -15.0K |
| Free cash flow | -9.15M | -8.43M | -10.5M | -28.4M | -21.6M | -21.6M | -12.5M | -12.5M | -13.0M | -13.0M |
| Cash from investing | 5.44M | 105.8M | -73.0M | 30.2M | -22.3M | -23.8M | 4.63M | 4.63M | 11.3M | 11.3M |
| Cash from financing | -4.74M | -52.0M | 52.0M | 10.8M | 101.4M | 102.9M | 23.8M | 23.8M | ||
| Dividends paid | -10.9M | |||||||||
| Share buybacks | -4.74M | -2.48M | 0 | |||||||
| Change in cash | -8.47M | 45.4M | -31.4M | 13.0M | 57.9M | 57.9M | 16.0M | 16.0M | -1.67M | -1.67M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Aug 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 3, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 30, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 19, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 14, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 31, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 20, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 19, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 31, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 30, 2025 | Current report | SEC |
| 8-K · Current report | Nov 17, 2025 | Results | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Nov 17, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2025 | Results | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 28, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 21, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 23, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Jul 16, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 16, 2025 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Jul 16, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | May 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Material contract | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 27, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| 8-K · Current report | Oct 8, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 26, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 16, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 21, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jun 20, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 20, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | May 10, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Mar 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 19, 2024 | Current report | SEC |
| 8-K · Current report | Mar 18, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 18, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 18, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 19, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Sep 26, 2023 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2023 | Current report | SEC |
| 8-K · Current report | Aug 21, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 8-K · Current report | Jul 13, 2023 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | May 31, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | May 31, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2023 | Insider trade | SEC |
| 8-K · Current report | May 1, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 6, 2023 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2023 | Current report | SEC |
| 8-K · Current report | Jan 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2022 | Current report | SEC |
| 8-K · Current report | Nov 14, 2022 | Current report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2022 | Insider trade | SEC |
This page holds 200 of 952 filings. Open Filings
Cap table
Built by 6ix from Oramed Pharmaceuticals Inc.’s releases · as of Nov 11, 2026
- Common shares
- 43,485,942
- Fully diluted
- 43,485,942
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 43,485,942 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 43,485,942 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kevin Rakin Other companies: Elutia, Inc. (Chairman · Since at least Oct 7, 2020); Quantum-Si Incorporated (Director · Since at least Sep 3, 2020); Ocugen, Inc. (Director · Dec 2, 2014 – Feb 8, 2019 · Past) | Director · Aug 30, 2016 – Mar 21, 2022 · Past |
| Nadav Kidron Other companies: Nano Dimension Ltd (Director · Since at least Aug 16, 2026); Lifeward Ltd. (Director · Since at least Mar 25, 2026); Alpha Tau Medical Ltd (Director · Since at least May 12, 2025) | President and CEO, Director · Since at least Feb 3, 2006 |
| Alex Weber Other companies: Blue Sphere Corp (Chief Financial Officer · Apr 8, 2010 – Apr 8, 2010 · Past); Global Energy Holdings Group Inc (Treasurer & CFO · May 6, 2007 – May 6, 2007 · Past) | Treasurer & CFO · Aug 1, 2007 – Aug 1, 2007 · Past |
| Avraham Gabay Other companies: Lifeward Ltd. (Director · Since at least Aug 20, 2026); BiomX Inc. (Interim CFO · Dec 6, 2023 – Dec 6, 2023 · Past) | Chief Financial Officer · Since at least Jun 18, 2024 |
| David Silberman Other companies: Compugen Ltd. (Chief Financial Officer · Since at least Mar 18, 2026); Nasus Pharma Ltd. (Board Member · Since at least Mar 18, 2026) | Chief Financial Officer · Jul 5, 2021 – Jan 4, 2024 · Past |
| Harold Jacob Other companies: ENvue Medical, Inc. (Chief Medical Officer, Director · Apr 10, 2015 – Dec 30, 2024 · Past) | Director · Aug 8, 2012 – Mar 10, 2016 · Past |
| Joshua Hexter Other companies: Lifeward Ltd. (Interim Chief Executive Officer · Since Sep 1, 2026 · Appointed, no departure found) | COO & CBO · Since at least Apr 14, 2013 |
| Miriam Kidron Other companies: Lifeward Ltd. (Director · Since at least Mar 25, 2026) | Chief Scientific Officer, Director · Since at least Dec 31, 2025 |
| Ronald Edward Law Other companies: BioSpecifics Technologies Corp (SVP Business Development · Jan 23, 2019 – Jan 23, 2019 · Past) | Chief Strategy Officer · Mar 20, 2017 – Mar 20, 2017 · Past |
| Yehuda Reznick Other companies: Lifeward Ltd. (Director · Since at least Mar 25, 2026) | Director · Since at least Apr 1, 2024 |
All 19 people
| Person | Seat |
|---|---|
| Arie Mayer | Director · Since at least Jan 4, 2024 |
| Benjamin Shapiro | Director · Since at least Jan 4, 2024 |
| Daniel Aghion | Director · Since at least Nov 12, 2026 |
| David Mark Slager | Director · Aug 30, 2016 – Apr 15, 2019 · Past |
| Leonard Sank | Director · Since at least Oct 23, 2007 |
| Mark Daniel Hasleton | VP Business Development · Nov 15, 2018 – Feb 26, 2019 · Past |
| Michael Rabinowitz | Chief Commercial Officer · Aug 1, 2021 – Jan 3, 2023 · Past |
| Netanel Derovan | Chief Legal Officer · Jan 9, 2022 – May 26, 2023 · Past |
| Yifat Hen Zommer | CFO, Treasurer and Secretary · Apr 19, 2009 – Jun 30, 2017 · Past |
Log in to ask 6ix AI your own questions about Oramed Pharmaceuticals Inc.